Astra Formedic S.R.L.

Astra Formedic S.R.L., an Italian for-profit medical device manufacturer based in Milan, supplies specialized medical quality control products and diagnostic testing supplies to the Defense Health Agency as a prime contractor under a single-award indefinite delivery contract. The vendor operates exclusively in the full-and-open competitive space with no set-aside designations across its federal footprint.

Astra Formedic's capability portfolio centers on cell check controls, ESR controls, and related diagnostic quality assurance products for automated hematology and blood analysis equipment used in military medical facilities. Representative work includes a $12.7 million firm-fixed-price delivery order awarded by the Defense Health Agency in January 2022 for Cell Check Controls Auto supplies; an $8.8 million delivery order in January 2023 for the same product line; and a $8.6 million delivery order issued in January 2026 for ESR-CHEX control items. All performance occurs in Italy, where Astra Formedic supplies U.S. Naval Hospital Naples and other military medical facilities in the region.

Astra Formedic's customer concentration is singular. The Defense Health Agency accounts for 13 of 15 awards and $222 thousand of the combined $241 thousand potential value across the vendor's federal footprint; the Department of the Navy Bureau of Medicine and Surgery holds the remaining 2 awards and $20 thousand. The vendor operates under two single-award indefinite delivery contracts. The primary vehicle, IDC N6817119D2008 originally issued by the Navy Bureau of Medicine and Surgery and the Defense Health Agency in September 2019, anchors 10 task orders with $70 thousand combined potential value and an extended ceiling now running through February 2, 2030. The secondary vehicle, IDC N6817125D2001, carries 3 task orders and $21 thousand in combined potential value.

Activity has been sparse and uneven. The vendor received 2 awards in 2022, 2 in 2023, 4 in 2024, 1 in 2025, and 1 in early 2026, with no sustained growth trajectory. Combined dollars obligated stand at $90 thousand against $241 thousand combined potential value—a 37% execution rate—suggesting modest invoicing velocity against the primary IDC. Only one award (valued at $9 thousand) reaches ultimate completion within the next twenty-four months, indicating minimal recompete pressure in the near term. The vendor operates without subcontractors on these awards, delivering the full scope as prime.